China's National Medical Products Administration (NMPA) has cleared an IND for CM-369, an anti-CC chemokine receptor 8 (CCR8) monoclonal antibody, developed by Tiannuojiancheng Pharma, a joint venture between InnoCare Pharma and Keymed Biosciences.